CTKB — Cytek Biosciences, Inc.

Summary of Cytek Biosciences Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenue was $44.1 million, a 6% increase from $41.5 million in Q1 2025.
• Product Revenue: Comprising instruments and reagents, product revenue was $28.8 million, up approximately 2% year-over-year.
• Recurring Revenue: Grew 19% year-over-year to $18.4 million, representing 35% of total revenue.
• Service Revenue: Increased by 15% year-over-year to $15.4 million.
• Gross Profit: GAAP gross profit was $21.3 million, with a gross margin of 48%, slightly down from 49% in Q1 2025.
• Net Loss: GAAP net loss was $18.9 million, compared to a loss of $11.4 million in the prior year.
• Adjusted EBITDA: Loss of $9.1 million, worsening from a loss of $3.3 million in Q1 2025.
• Cash Position: Cash, cash equivalents, and marketable securities totaled $262.2 million.

2. Strategic Updates and Business Highlights

• Geographic Performance:
  • U.S. revenue grew 32% year-over-year to $24.4 million, driven by strong demand from academic and biopharma sectors.
  • EMEA revenue declined 7% due to geopolitical disruptions and shipment delays.
  • APAC revenue fell 13%, primarily due to order timing issues in China, although other regions showed strong growth.
• Product Innovations: The Cytek Aurora Evo analyzer has driven revenue growth, with a notable increase in installed units (totaling 3,789).
• Business Structure: The company plans to refocus operations into three distinct business units by Q3 2026, aiming to enhance market alignment and growth opportunities.

3. Forward Guidance and Outlook

• Full Year 2026 Revenue Guidance: Reaffirmed guidance of $205 million to $212 million, assuming stable currency exchange rates.
• Growth Expectations: Anticipate continued growth in services and reagents, with flat to modest growth in instruments. The guidance includes a contingency for macroeconomic risks.

4. Challenges and Points of Concern

• Increased Operating Expenses: Total operating expenses rose 13% year-over-year, with significant increases in general and administrative expenses due to legal costs and consulting fees.
• Net Loss Increase: The net loss widened due to higher operating expenses and foreign exchange losses.
• Market Risks: Ongoing uncertainties regarding NIH funding could impact future demand from academic and government sectors, although Q1 performance was strong.

5. Notable Q&A Insights

• Customer Mix: In Q1, 62% of customers were from biopharma, while 38% were from academic and government sectors. The Aurora Evo instrument has been well-received in both segments.
• Impact of NIH Funding: Despite concerns, Q1 showed strong performance in the U.S. academic and government sectors, suggesting resilience against funding uncertainties.
• Sales and Marketing Investments: Although sales and marketing expenses declined in Q1, the company plans to continue aggressive investment in these areas for the remainder of the year.

This summary encapsulates the key points from Cytek Biosciences' Q1 2026 earnings call, highlighting financial performance, strategic initiatives, future guidance, and potential challenges.